Bank of America’s CRISPR Therapeutics CRSP Stock Holding History

Bank of America’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,000	Closed	-$130K	–	7544
2025 Q3	$130K	Hold	2,000	–	–	﹤0.01%	6482
2025 Q2	$97.3K	Buy	+2,000	New	+$77.4K	﹤0.01%	6528
2024 Q3	–	Sell	-71,600	Closed	-$3.87M	–	8201
2024 Q2	$3.87M	Sell	71,600 -49,300	-41%	-$2.85M	﹤0.01%	3854
2024 Q1	$8.24M	Sell	120,900 -10,000	-8%	-$716K	﹤0.01%	3167
2023 Q4	$8.19M	Buy	+130,900	New	+$7.24M	﹤0.01%	3096
2023 Q3	–	Sell	-800	Closed	-$44.9K	–	7788
2023 Q2	$44.9K	Buy	+800	New	+$45.4K	﹤0.01%	6498
2022 Q1	–	Sell	-160,700	Closed	-$12.2M	–	8329
2021 Q4	$12.2M	Sell	160,700 -65,300	-29%	-$5.7M	﹤0.01%	2728
2021 Q3	$25.3M	Sell	226,000 -40,400	-15%	-$5.07M	﹤0.01%	1954
2021 Q2	$43.1M	Buy	266,400 +260,000	+4,063%	+$31.6M	﹤0.01%	1467
2021 Q1	$780K	Sell	6,400 -29,100	-82%	-$4.39M	﹤0.01%	5030
2020 Q4	$5.43M	Buy	+35,500	New	+$4.2M	﹤0.01%	3056

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $599M AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of America's CRSP Position: Q1 2026 in Review

Bank of America reduced its CRISPR Therapeutics (CRSP) stake by 10% in Q1 2026, selling an estimated $6M and leaving 983,072 shares worth $46.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1645.

Bank of America first reported a position in CRSP in Q4 2016 and has held it in 38 quarters since. The position peaked at $96.1M in Q3 2022. 490 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

Bank of America held 983,072 shares of CRISPR Therapeutics worth $46.8M as of Q1 2026.
Bank of America sold 113,815 CRISPR Therapeutics shares in Q1 2026, an estimated $6M.
CRISPR Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #1645 holding.
Bank of America first reported a position in CRISPR Therapeutics in Q4 2016 and has held it in 38 quarters since.
Bank of America's CRISPR Therapeutics position peaked at $96.1M in Q3 2022.
490 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.